Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C

Hepatology International

Volumn 8, Issue 4, 2014, Pages 560-566

  Narayanan, Shivakumar ^a   Townsend, Kerry ^b   Macharia, Thomas ^a   Majid, Adrian ^a   Nelson, Amy ^b   Redfield, Robert R ^a   Kottilil, Shyam ^b   Talwani, Rohit ^a   Osinusi, Anu ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adverse events; HCV monoinfection; Ribavirin; Sofosbuvir

Indexed keywords

BOCEPREVIR; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERBILIRUBINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 84919876697     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-014-9574-0     Document Type: Article

References (24)

1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20(1):17–35.
2. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002;36(5 Suppl 1):S30–S34.
3. Ly KN, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012;156(4):271–278.
4. Mohd Hanafiah K, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333–1342.
5. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology 2009;50(2):387–392.
6. Bacon BR, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1207–1217.
7. Hezode C, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360(18):1839–1850.
8. McHutchison JG, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360(18):1827–1838.
9. Kwo PY, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376(9742):705–716.
10. Poordad F, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364(13):1195–1206.
11. Sherman KE, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365(11):1014–1024.
12. Fried MW, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013;58(6):1918–1929.
13. Gane EJ, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368(1):34–44.
14. Osinusi A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013;310(8):804–811.
15. Gane EJ, Stedman CA, Hyland RH, et al. Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the ELECTRON trial. Hepatology. 2012;56(suppl):306A–307A.
16. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;369(7):678–679.
17. Sovaldi, Sovaldi (sofosbuvir) tablets: US prescribing information. http://www.sovaldi.com/, Dec 2013.
18. Division of AIDS table for grading the severity of adult and pediatric adverse events, December 2004. (http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf).
19. Jacobson IM, Kowdley KV, Kwo PY. Anemia management in the era of triple combination therapy for chronic HCV. Gastroenterol Hepatol (N Y) 2012;8(9 Suppl 6):1–16.
20. Maasoumy B, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013;8(2):e55285.
21. Majid A, et al. Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection. J Viral Hepat. 2014;21(8):585–589.
22. Lawitz E, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368(20):1878–1887.
23. Naggie S, Sulkowski M, Lalezari J, et al. Sofosbuvir plus ribavirin for HCV genotype 1–3 infection in HIV coinfected patients (PHOTON-1). (Abstract 26) Presented at Conference on Retroviruses and Opportunistic Infections; 2014 March 4. Boston; 2014.
24. Schmidt-Martin D, Houlihan D, McCormick A. From the CUPIC study: great times are not coming(?). J Hepatol 2014;60(4):899–900.